Artificial Intelligence: The New “Fuel” to Accelerate Pharmaceutical Development

Panteleimon      Pantelidis; Michael      Spartalis; George      Zakynthinos; Artemis      Anastasiou; Athina      Goliopoulou; Evangelos      Oikonomou; Dimitrios   C.   Iliopoulos; Gerasimos      Siasos

Keywords: Artificial intelligence, big data, development, drug, healthcare, pharmaceutical.

[1] 
 The Business Research Company. AI in pharma global market. 2021. Available from:  www.researchandmarkets.com/reports/5459422/ai-in-pharma-global-market-opportunities-and
[2] 
Kok JN, Boers EJ, Kosters WA, Van der Putten P, Poel M. Artificial intelligence: Definition, trends, techniques, and cases. Artif Intell  2009; 1: 270-99.
[3] 
Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today  2021; 26(1): 80-93.
[http://dx.doi.org/10.1016/j.drudis.2020.10.010] [PMID:  33099022] 
[4] 
Duch W, Swaminathan K, Meller J. Artificial intelligence approaches for rational drug design and discovery. Curr Pharm Des  2007; 13(14): 1497-508.
[http://dx.doi.org/10.2174/138161207780765954] [PMID:  17504169] 
[5] 
Zang Q, Mansouri K, Williams AJ, et al. 
              In silico
            
             prediction of physicochemical properties of environmental chemicals using molecular fingerprints and machine learning.
           J Chem Inf Model  2017; 57(1): 36-49.
[http://dx.doi.org/10.1021/acs.jcim.6b00625] [PMID:  28006899] 
[6] 
Powles J, Hodson H. Google DeepMind and healthcare in an age of algorithms. Health Technol  2017; 7(4): 351-67.
[http://dx.doi.org/10.1007/s12553-017-0179-1] [PMID:  29308344] 
[7] 
Cichonska A, Pahikkala T, Szedmak S, et al. Learning with multiple pairwise kernels for drug bioactivity prediction. Bioinformatics  2018; 34(13): i509-18.
[http://dx.doi.org/10.1093/bioinformatics/bty277] [PMID:  29949975] 
[8] 
Genheden S, Thakkar A, Chadimová V, Reymond JL, Engkvist O, Bjerrum E. AiZynthFinder: A fast, robust and flexible open-source software for retrosynthetic planning. J Cheminform  2020; 12(1): 70.
[http://dx.doi.org/10.1186/s13321-020-00472-1] [PMID:  33292482] 
[9] 
Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics  2019; 20(2): 273-86.
[http://dx.doi.org/10.1093/biostatistics/kxx069] [PMID:  29394327] 
[10] 
Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun  2018; 11: 156-64.
[http://dx.doi.org/10.1016/j.conctc.2018.08.001] [PMID:  30112460] 
[11] 
Qi Y, Tang Q. Predicting phase 3 clinical trial results by modeling phase 2 clinical trial subject level data using deep learning. Mach Learn Healthc Conf PMLR  2019; 106: 1-14.
[12] 
Hirschberg C, Edinger M, Holmfred E, Rantanen J, Boetker J. Image-based artificial intelligence methods for product control of tablet coating quality. Pharmaceutics  2020; 12(9): 877.
[http://dx.doi.org/10.3390/pharmaceutics12090877] [PMID:  32942536] 
[13] 
Lamberti MJ, Wilkinson M, Donzanti BA, et al. A study on the application and use of artificial intelligence to support drug development. Clin Ther  2019; 41(8): 1414-26.
[http://dx.doi.org/10.1016/j.clinthera.2019.05.018] [PMID:  31248680] 
[14] 
Harrow I, Balakrishnan R, Küçük McGinty H, Plasterer T, Romacker M. Maximizing data value for biopharma through FAIR and quality implementation: FAIR plus Q. Drug Discov Today  2022; 27(5): 1441-7.
[http://dx.doi.org/10.1016/j.drudis.2022.01.006] [PMID:  35066138] 
[15] 
Batra K, Zorn KM, Foil DH, et al. Quantum machine learning algorithms for drug discovery applications. J Chem Inf Model  2021; 61(6): 2641-7.
[http://dx.doi.org/10.1021/acs.jcim.1c00166] [PMID:  34032436] 

Cite As

Current Pharmaceutical Design

Artificial Intelligence: The New “Fuel” to Accelerate Pharmaceutical Development